$206 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 32 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 51.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXSM | Sell | AXSOME THERAPEUTICS INC | $18,149,000 | -71.1% | 308,500 | -49.2% | 8.80% | -43.4% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $11,959,000 | -34.2% | 399,500 | -39.1% | 5.80% | +28.8% |
| ARVN | Sell | ARVINAS INC | $11,289,000 | -22.8% | 280,120 | -21.3% | 5.47% | +51.0% |
| AUPH | Sell | AURINIA PHARMACEUTICALS INC | $11,173,000 | -47.9% | 770,000 | -27.2% | 5.42% | +2.1% |
| KDMN | Sell | KADMON HLDGS INC | $9,888,000 | -63.9% | 2,360,000 | -60.9% | 4.79% | -29.3% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $7,127,000 | -40.7% | 628,500 | -31.5% | 3.45% | +15.9% |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $4,712,000 | -44.8% | 256,500 | -33.8% | 2.28% | +8.0% |
| CNST | Sell | CONSTELLATION PHARMCETICLS I | $4,383,000 | -52.9% | 139,464 | -29.4% | 2.12% | -7.8% |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $3,392,000 | -56.3% | 23,500 | -38.2% | 1.64% | -14.6% |
| APLT | Sell | APPLIED THERAPEUTICS INC | $3,334,000 | -17.4% | 102,000 | -31.1% | 1.62% | +61.6% |
| ARWR | Sell | ARROWHEAD PHARMACEUTICALS IN | $3,156,000 | -88.8% | 109,700 | -75.2% | 1.53% | -78.0% |
| KURA | Sell | KURA ONCOLOGY INC | $1,970,000 | -40.3% | 198,000 | -17.5% | 0.96% | +16.9% |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS | $500,000 | -94.9% | 250,000 | -91.2% | 0.24% | -90.0% |
| ISEE | Sell | IVERIC BIO INC | $478,000 | -93.9% | 139,000 | -84.7% | 0.23% | -88.0% |
| XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -40,000 | -100.0% | -0.11% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INCcall | $0 | – | -100,000 | -100.0% | -0.28% | – |
| CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -35,000 | -100.0% | -0.34% | – |
| ACST | Exit | ACASTI PHARMA INCcl a new | $0 | – | -620,000 | -100.0% | -0.38% | – |
| MDCO | Exit | MEDICINES CO | $0 | – | -21,700 | -100.0% | -0.46% | – |
| KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -107,500 | -100.0% | -0.47% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -150,000 | -100.0% | -0.79% | – |
| ZYME | Exit | ZYMEWORKS INC | $0 | – | -70,500 | -100.0% | -0.79% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INCcall | $0 | – | -100,000 | -100.0% | -0.85% | – |
| INSM | Exit | INSMED INC | $0 | – | -169,000 | -100.0% | -1.00% | – |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -372,500 | -100.0% | -1.14% | – |
| MIST | Exit | MILESTONE PHARMACEUTICALS IN | $0 | – | -508,500 | -100.0% | -2.02% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -590,000 | -100.0% | -2.80% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INC | $0 | – | -587,089 | -100.0% | -4.99% | – |
| XBI | Exit | SPDR SERIES TRUSTput | $0 | – | -500,000 | -100.0% | -11.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.